The 8 analysts offering 12-month price forecasts for Atara Biotherapeutics Inc have a median target of 27.50, with a high estimate of 78.00 and a low estimate of 10.00. The median estimate represents a +56.16% increase from the last price of 17.61.
The current consensus among 10 polled investment analysts is to Buy stock in Atara Biotherapeutics Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.75
Reporting Date Mar 03
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.